ORT456669_sm_Figures.pdf (632.26 kB)
Supplementary Material for: Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance
Version 2 2017-03-21, 08:56
Version 1 2017-03-21, 07:34
journal contribution
posted on 2017-03-21, 08:56 authored by Zhang L., Li N., Yan H.C., Jiang H., Fang X.J.Background: Abnormal expression of some CD44 molecules
in tumor tissues can induce the degradation of the
extracellular matrix, and is closely associated with axillary
lymph node metastasis, angiogenesis, cancer progression,
and drug resistance. Patients and Methods:
We measured and confirmed the expression of CD44st
and MMP2 mRNAs and proteins in the cancer tissues
and adjacent normal tissues of postoperative non-small
cell lung cancer (NSCLC) patients with either adenocarcinoma
(n = 72) or squamous cell carcinoma (n = 53) using
quantitative reverse transcription polymerase chain reaction,
gene sequencing, and immunohistochemical
analysis. Results: CD44st and MMP2 expression were
closely associated with the histopathological classification,
lymph node metastasis, and TNM stage of the tumors,
and the difference was statistically significant (p
< 0.05). The median overall survival (OS) for the high
CD44st expression group was 30.52 months (95% confidence
interval (CI) 24.02–36.15); for the low expression
group it was 43.23 months (95% CI 31.81–52.02) (p = 0.020).
The median OS for the high MMP-2 expression group
was 30.53 months (95% CI 26.69–33.31); for the low expression
group it was 40.06 months (95% CI 33.55–46.45)
(p = 0.022). Conclusion: The rates of CD44st and MMP2
expression were higher in squamous cell carcinomas than in adenocarcinomas, were closely associated with
lymph node metastasis and TNM stage, and affected patients’
prognoses